Head to Head Comparison: Celsion (CLSN) & Agile Therapeutics (AGRX)

Celsion (NASDAQ: CLSN) and Agile Therapeutics (NASDAQ:AGRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, earnings, institutional ownership, risk, profitability and valuation.

Volatility & Risk

Celsion has a beta of 1.22, indicating that its stock price is 22% more volatile than the S&P 500. Comparatively, Agile Therapeutics has a beta of 2.03, indicating that its stock price is 103% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current recommendations and price targets for Celsion and Agile Therapeutics, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Celsion 0 0 4 0 3.00
Agile Therapeutics 0 0 6 0 3.00

Celsion currently has a consensus target price of $14.50, indicating a potential upside of 423.47%. Agile Therapeutics has a consensus target price of $10.20, indicating a potential upside of 113.84%. Given Celsion’s higher possible upside, equities research analysts clearly believe Celsion is more favorable than Agile Therapeutics.

Profitability

This table compares Celsion and Agile Therapeutics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Celsion -4,292.80% -282.94% -59.69%
Agile Therapeutics N/A -81.68% -53.67%

Institutional & Insider Ownership

4.2% of Celsion shares are owned by institutional investors. Comparatively, 73.0% of Agile Therapeutics shares are owned by institutional investors. 3.8% of Celsion shares are owned by company insiders. Comparatively, 5.1% of Agile Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Celsion and Agile Therapeutics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Celsion $500,000.00 88.97 -$22.05 million ($5.83) -0.47
Agile Therapeutics N/A N/A -$28.74 million ($0.92) -5.18

Celsion has higher revenue and earnings than Agile Therapeutics. Agile Therapeutics is trading at a lower price-to-earnings ratio than Celsion, indicating that it is currently the more affordable of the two stocks.

Summary

Agile Therapeutics beats Celsion on 8 of the 11 factors compared between the two stocks.

Celsion Company Profile

Celsion Corporation is an oncology drug development company. The Company’s product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Agile Therapeutics Company Profile

Agile Therapeutics, Inc. is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch. In addition to Twirla, the Company is developing a pipeline of other new transdermal contraceptive products, including AG200-ER, which is a regimen designed to allow a woman to extend the length of her cycle; AG200-SP, which is a regimen designed to provide a shortened hormone-free interval, and AG890, which is a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen. Each of its product candidates utilizes its Skinfusion technology designed to deliver contraceptive-levels of hormones to the blood stream through the skin over a seven-day period.

Receive News & Ratings for Celsion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celsion and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply